Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR-PARTNER-RA
ISRCTN94259329Phase 4Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of abatacept, methotrexate and Placebo-COD Research Private Ltd in rheumatoid arthritis (RA) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Clinical Disease Activity Index. Started Jun 2025; status: recruiting.
02
Drugs
abataceptmethotrexatePlacebo-COD Research Private Ltd
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN94259329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94259329.